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Abstract: This is a case study based on the author’s experi-
ence while serving as an ethics committee (IRB) chair in 
New York City. It addresses the issues of power and coercion 
as they apply to the human research participants protection 
process. It primarily focuses on the power imbalance that can 
exist between research participants and their IRB advocates 
on the one hand and the research institutions, funding agen-
cies, and investigators with their unlimited resources on the 
other. IRB Chairs and IRB leaders must be fire-walled from 
conflicts of interest arising not just from financial factors but 
from factors related to power, hierarchy, structure, and con-
trol. Senior staff, IRB members, administrators and ethicists 
best advocate for human volunteers in research through per-
sonal identification and solidarity. 
Keywords: power, influence, hierarchy, control, IRB auton-
omy, advocacy 
Until recently, I chaired a fairly high volume, behavioral and biomed-ical sciences Institutional Review Board (IRB) for an institution in New York City that was centrally 
positioned for numerous collaborative national re-
search investigations. About midway in my tenure 
there, a particularly sensitive and apparently risky 
joint protocol came before the Board from a princi-
pal investigator (PI) who was associated with a ma-
jor research institution in our area. After I had desig-
nated that the protocol needed full board review, the 
PI, as requested, came and presented to the Board 
at a formal IRB meeting. Subsequently, an exten-
sive dialogue ensued over how to properly address 
human research protections for this research, which 
seemed to offer the hope of significant benefit if con-
ducted appropriately. With a better understanding of 
the complexity and implications of the research, the 
Board decided to appoint an appropriate primary re-
viewer who did a substantial review of the literature 
in the subject area to assist in the risk/benefit analy-
sis. After going over the primary reviewer’s report, 
it was decided that several modifications and addi-
tions needed to be made in the proposed participant 
protection process. The Board considered it neces-
sary to substantially raise the federal regulatory bar 
by requiring more than the minimum protections. 
The requested changes were delineated, explained, 
and sent on to the PI for compliance. 
About a week later the PI phoned, asking if I 
would drop or weaken the stipulations, and I ex-
plained that the Board would not do that. In any 
event, I explained, I certainly did not have the au-
thority to unilaterally counter the Board’s wishes 
even if I wanted to. I told her she could prepare a re-
sponse to the Board if she wished, which would be 
sent to them for review and discussion at the next 
meeting. She said her legal office, which had direct 
advisory responsibilities for all research compliance 
issues, would not allow her to make the changes re-
quested. She said they were concerned about liabil-
ity and institutional autonomy. After some discus-
sion I realized the core concern was that the Board 
in this case had raised the regulatory bar beyond the 
federal minimum and stipulated that compensation 
in the event of medical injury would be required be-
cause of the very risky nature of the research. I ul-
timately replied that it would be unfortunate to not 
make the required changes since the research ap-
peared to promise substantial benefit. She suggested 
that perhaps her legal counsel could be persuaded if 
they heard the explanation of our decision from me, 
so I agreed to meet with her and her counsel to dis-
cuss the matter. 
A week later she called again asking if it might be 
possible for me to come by for an informal discus-
sion about the protocol. I agreed and a few days later 
went to see them. When I walked into what I thought 
would be an office or a meeting room, I quickly real-
ized it was the conference room adjoining the office 
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of the president of the institution. Within a moment 
the president, general counsel, and PI walked into the 
room from his office, and I was smilingly introduced. 
After a minute of small talk, the general counsel 
jumped right in stating that it was unprecedented and 
impossible for them to comply with our requests, and 
that it was “arbitrary and capricious” for the IRB to ask 
for anything above and beyond the requirements of 
the federal regulations without formally putting it into 
our policies beforehand. I pointed out that our policies 
clearly state that the federal and state regulations are 
minimal standards, and that the IRB has the flexibil-
ity, discretion and empowerment to raise that bar as it 
feels necessary for each individual case. For this proto-
col the Board, acting as the participants’ advocate, de-
cided it was necessary to insist on greater protections 
for their well-being. 
I then began to explain our reasoning for each stip-
ulation. At that point, with no forewarning, the pres-
ident interrupted and said that there was no need to 
discuss this further. I simply had to make the adjust-
ments to fit their criteria. I said I would not do that 
and could not besides. In a split second his whole de-
meanor went from charm to a furious indignation. He 
looked at me and said he knew the person who headed 
my organization, and that he would have my “head on 
a plate” if I did not comply with their request. For the 
next five minutes or so, I sat in stunned disbelief while 
the president and the general counsel unloaded. When 
I regained my senses, I got up, said the Board’s posi-
tion was clear, excused myself and left. 
Later that day, I reported what had happened to the 
head of my organization, who said it was hard to imag-
ine since she knew the president to be “such a charm-
ing, witty and gracious person,” but that a call would 
be made to remind him of the IRB’s independent au-
thority. In addition, I reported the incident back to the 
full IRB; they supported my actions without reserva-
tion. I did receive a follow-up phone call from the gen-
eral counsel who said that perhaps the meeting did not 
go as smoothly as they would have preferred. My re-
sponse was to say that that was totally of their making. 
When asked if I had given the protocol some further 
thought, I said that there was nothing to think about. 
I also pointed out that thankfully we had supportive 
organizational leadership, and in addition, I was pro-
tected by what was comparable to tenure. We never 
spoke again regarding the protocol. I heard from pro-
fessional acquaintances that the general counsel had 
also approached OHRP for support and been told our 
IRB was perfectly within its rights and responsibilities. 
Over the next few months the PI submitted a series of 
revisions that ultimately complied with all of our orig-
inal requests. In a nutshell, although I left the meeting 
that day trembling with anger, nothing changed for 
the PI or the protocol except for a lengthy delay in the 
approval process until the PI complied fully with the 
original stipulations. 
Lessons Learned
I learned several lessons from this incident: First, 
never give up home-court advantage, i.e., all subse-
quent meetings with PIs and/or their advocates would 
take place in my office or our conference room. Sec-
ond, I made it a point always to have our lawyer with 
me when chatting with those who ask if it is okay 
to have their lawyer sit in. There is no such thing as 
a conversation with benign intent when someone 
wants their lawyer nearby. This has carried through 
to my personal life as well. A third lesson that I have 
preached religiously since that day is that for the over-
all health and effectiveness of the human research pro-
tection system, organizations should insure that IRB 
chairs have tenure or something comparable. Chairing 
an IRB is not a job for a junior faculty member or the 
equivalent. I am glad I was able to stand up to a pow-
erful and well-connected person in a challenging sit-
uation, but unfortunately it is not always the case that 
we have the luxury of security in those circumstances. 
Sadly, the theme of this anecdote was not an iso-
lated circumstance for me; it has presented itself, in 
different characters and guises, a number of times over 
the years. Sponsors, investigators or institutions in one 
way or another made veiled, or not so veiled, threats 
or perhaps more judiciously, disquieting suggestions. 
Overcoming the Empathic Divide
I am a social psychologist by training, so you can guess 
perhaps that there is more of a point in this rendering 
than the very obvious lessons mentioned above. I want 
the reader to reflect on the empathetic divide that of-
ten exists between researchers, including those who 
support them, and the research participants, who are 
the foundation of their enterprise. This gulf exists even 
when there are the best of intentions. As a result, there 
can be considerable ambiguity about the motives of 
those investigators and gatekeepers who behave with-
out due regard for the welfare of research participants. 
For example, without proof to the contrary, I would 
agree with one commentator’s assertion regarding the 
Johns Hopkins incident in which a research partic-
ipant died as a direct result of the research in which 
she was participating. He said: “The issue is not inten-
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tional harm, but perhaps ignorance.”1 Unless the ethics 
committee actively advocates for research participants, 
those responsible for harming participants are unlikely 
to be held to account. In the case I described here, if 
the IRB had allowed the study to run as originally pre-
sented, would the president have been accused of in-
tentional harm had something gone amiss and the 
participant took the brunt of the consequences? Of 
course not. But can ignorance be a valid excuse when 
there is resistance to, or avoidance of, understanding 
the positions, vulnerabilities and needs of all those in-
volved in the enterprises for which one is responsi-
ble? I would suggest that the president was not open to 
an explanation from me for the IRB’s actions because 
neither empathetically nor in terms of accountability 
did he feel the need to hear such an account. I repre-
sented an entity outside of his realm of significant oth-
ers. The research participant and the IRB were not rel-
evant issues. His perceived constituency was limited to 
those to whom he was immediately accountable, and 
he knew their desires and objectives. Appropriately, 
though, the IRB also understood who its constituency 
was and was willing to assert itself. So this becomes a 
graphic example that it is only through an assertive, 
vocal, aware and independent IRB that the research 
protection process can work effectively.
However, this was not a unique example. Many 
within the research community are unlikely to look 
upon research participants as “us,” but more likely as 
“them”. A quote from Albert Schweitzer (1965, p. 9) is 
a gem in this regard: “The first step in the evolution 
of ethics is a sense of solidarity with other human be-
ings.” Sociologists similarly often speak of the need to 
become the other to truly understand a situation. In 
this vein, when I hear about some advocacy organiza-
tion or individual being too extreme in their promo-
tion of participants’ rights and safety, I am reminded 
of Richard Rorty’s Contingency, Irony, and Solidar-
ity (Rorty, 1989), and of its review by George Scial-
abba (1989) in which he discusses one of Rorty’s main 
themes, that philosophy and ideology alone make 
nothing happen: they are politically useless. “Progress 
depends rather on extending our imaginative range 
. . .  identifying with those who are unnecessarily suf-
fering” (Scialabba, 1989, p. 686). Scialabba relates that 
this process of extending the imaginative range is one 
for storytellers, such as journalists and novelists. For 
example, about George Orwell, who was a focal point 
in Rorty’s book, Scialabba comments: 
Both as a journalist and a novelist, Orwell worked 
on his readers’ moral imagination, showing them 
suffering they had failed to notice and then show-
ing them what the best, the most intelligent, of 
them would turn into if this moral obtuseness 
overwhelmed the fragile structure of liberal-
ism. Rorty believes with Shelley, an earlier radical 
pragmatist, that “the great instrument of moral 
good is the imagination.” (p. 287)
So, “the great instrument of moral good is the 
imagination.” If we are responsible to, and more im-
portantly, for, others, then we need to reach outside 
our usual sources of information to those we might 
not at first be able to relate to. For example, advocacy 
organizations and their proponents are often crucial in 
helping us expand our imaginative and empathetic pa-
rameters. They compel us oftentimes to cross the con-
venient ignorance divide. 
Strong Advocacy
Bad stuff happens in this world, and those in apparent 
opposition to our complacent ideologies often bring 
a glimpse of that other reality. Personally, I wish we 
had more advocacy entities espousing sound research 
ethics and protections. For those who find advocates’ 
sense of decorum or methods of communication too 
histrionic, I remind them that my experience de-
scribed above is perhaps not all that unusual; I would 
bet there are many who have witnessed the “charming, 
witty and gracious person” in power become very in-
decorous when events do not evolve to their liking. A 
meek advocate would be no match for such a forceful 
opponent. 
The research process can lead to pain and suffer-
ing by the participants involved, but I think most of 
us would agree that there is concomitant greater good 
generated by its product. Research of the highest or-
der represents the active application of hope. Still, in 
an editorial in The Washington Post, Angell and Rel-
man (2001) point out: 
“Here are the facts: The pharmaceutical giants 
spend two or three times as much on marketing 
and administration as they do on R&D [research 
and development], and their profits are about 
twice their R&D costs. To cite a typical example, 
last year GlaxoSmithKline spent 37 percent of its 
revenues on marketing and administration and 
only 14 percent on R&D, while making a 28 per-
cent profit. Overall, the pharmaceutical industry 
is by far the most profitable in the United States” 
This translates into billions and billions of dollars. 
I am not trying to debate here how the pharmaceuti-
1 Robert Nelson, message on IRB Forum listserve (formerly 
mcwirb) entitled “The Debate Over Exposure to Research Risk 
without Direct Benefit,” June 21, 2001. 
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cal industry should spend its revenues. The point is 
that we are the recipients of a great deal of public re-
lations-type information on the product side of the 
research equation whether we like it or not. Indus-
try will always find ways to reach our cognitive senses 
with their intended messages. It is our responsibility in 
the research integrity and human research protection 
endeavor to reach beyond what is obviously apparent 
to a keener understanding of all sides and dimensions. 
We need to feel an obligation to those we represent to 
do all that we can to expand our imaginative range to 
what might be missing relative to the issues and cases 
we deliberate about and ultimately decide on. 
Ethics begins with our reflective consideration 
of the effects of our contemplated actions on others. 
Rorty and Schweitzer would go further still and say 
that true ethical behavior on our parts is impossible 
without a feeling of identification and solidarity with 
those we represent and advocate for. Therein lies our 
end but also our beginning. 
Best Practices
Three recommendations flow from the case described 
herein: (1) Meetings with powerful investigators and/
or funders should take place in IRB administrative 
offices. (2) IRB chairs and administrators need to be 
fire-walled from potential conflicts of interest arising 
not just from financial factors but from factors related 
to power, hierarchy, structure and control. (3) Effec-
tive ethical advocacy is best achieved through an edu-
cational emphasis on the development of empathy. 
Research Agenda
While the literature in social psychology provides un-
derstanding of coercion, there is need for a better un-
derstanding of the actual applied contexts that result in 
coercion of those responsible for advocacy, and of fac-
tors that enable them to resist coercion. Needed are: 
•    Educational techniques that would improve moral 
imagination in realistic and positive ways as op-
posed to imagining far-fetched risks where there 
are none. 
•    A clearer understanding of the fluidity and perme-
ability of the boundaries between self and other, us 
and them, with ethical decision-making as the ulti-
mate byproduct. 
Educational Implications
Ethical behavior and concomitant social progress are 
impossible without empathetic ability and altruistic 
concern. Education should be devoted to their devel-
opment through venues such as film, literature, drama, 
case analysis, music, story-telling and oration. 
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